Atorvastatin and statins in the treatment of heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Heart failure (HF) impacts millions globally with limited 5-year survival rates.
• Current medical and device therapies offer incremental benefits, highlighting the need for novel treatments.
• Statins, primarily known for lipid-lowering, possess pleiotropic effects with potential relevance to HF management.

Purpose of the Study:

• To explore the potential benefits of statin therapy in patients with heart failure.
• To investigate the non-lipid-related (pleiotropic) effects of statins in the context of HF.
• To summarize existing evidence and identify the need for further research in statin use for HF.

Main Methods:

• Review of observational studies and small prospective clinical trials involving statin therapy in HF cohorts.
• Analysis of statin's pleiotropic effects, including anti-inflammatory, endothelial function improvement, and autonomic balance restoration.
• Assessment of reported outcomes such as survival rates, ventricular systolic function, and inflammatory biomarkers.

Main Results:

• Observational studies consistently link statin use with improved survival in HF patients.
• Small clinical studies suggest statins can enhance ventricular systolic function and reduce inflammatory markers in systolic HF.
• Statin pleiotropic effects may include reversing myocardial remodeling and improving endothelial function.

Conclusions:

• Statins demonstrate promising pleiotropic effects that could benefit patients with both ischemic and non-ischemic heart failure.
• Evidence from observational and small clinical studies suggests improved survival and cardiac function with statin therapy.
• Large-scale outcome trials are essential to establish definitive recommendations for statin use in all HF populations, particularly non-ischemic HF.